The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTFB.L Regulatory News (MTFB)

  • There is currently no data for MTFB

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

25 Nov 2016 11:32

RNS Number : 1935Q
Motif Bio PLC
25 November 2016
 
 
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Motif Bio plc

2. Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

 

CHANGE IN NATURE : SHARES LOANED OUT &

CHANGE TO THE NUMBER OF VOTING RIGHTS IN ISSUE, FOLLOWING THE RECENT PUBLIC OFFER

 

3. Full name of person(s) subject to thenotification obligation: iii

Aviva plc & its subsidiaries

4. Full name of shareholder(s)  (if different from 3.):iv

Registered Holder:

 

Available on Request 5,944*

 

BNY Norwich Union Nominees Limited 99,767* 

Chase (GA Group) Nominees Limited 3,801,750*

 

State Street Nominees Limited 1,038,396*

*denotes direct interest

 

Chase (GA Group) Nominees Limited 1,698,925

 

Chase Nominees Limited 329,800

 

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

23 November 2016

6. Date on which issuer notified:

24 November 2016

7. Threshold(s) that is/are crossed orreached: vi, vii

 

4% to

>5% to

6% to 3% change at Direct Interest Level (Box 8A & 8B) and

>5% to

 

 

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

 

Ordinary Shares

 

GB00BVVT4H71

8,939,785*

8,939,785*

6,974,582

4,945,857

2,028,725

2.74%

1.12%

*Includes Right to Recall Loaned Shares (1,528,203)

 

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

RIGHT TO RECALL LOANED SHARES

N/A

N/A

 

1,965,203*

 

*Direct interest

1.09%

 

 

 

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

8,939,785

4.95%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

The voting rights are managed and controlled by Aviva Investors Global Services Limited & Friends Provident International Limited, with the following chain of controlled undertakings:-

 

Aviva Investors Global Services Limited:

· Aviva plc (Parent Company)

· Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc)

· Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited)

· Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)

 

Friends Provident International Limited:

· Aviva plc (Parent Company)

· Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc)

· Aviva Life Holdings UK Limited (wholly owned subsidiary of Aviva Group Holdings Limited)

· Friends Life FPG Limited (wholly owned subsidiary of Aviva Life Holdings UK Limited)

· Friends Life FPL Limited (wholly owned subsidiary of Friends Life FPG Limited)

· Friends Life Limited (wholly owned subsidiary of Friends Life FPL Limited)

· Friends Life and Pensions Limited (wholly owned subsidiary of Friends Life Limited)

· Friends Provident International Limited (wholly owned subsidiary of Friends Life and Pensions Limited)

 

Proxy Voting:

10. Name of the proxy holder:

See Section 4

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

Figures are based on the total number of voting rights of 180,643,744 as per the Company's 'Closing of Public Offer' announcement of 23 November 2016.

 

14. Contact name:

Neil Whittaker, Aviva plc

15. Contact telephone number:

01603 684420

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLLLFFLLTLEFIR
Date   Source Headline
17th Apr 20187:00 amRNSPosting of UK Annual Report and Notice of AGM
11th Apr 20182:30 pmRNSIclaprim Abstracts for ECCMID 2018 Now Online
10th Apr 20187:00 amRNSFiscal Year 2017 Results
3rd Apr 20183:29 pmRNSHolding(s) in Company
3rd Apr 20187:00 amRNSInitiation of NDA Rolling Submission for Iclaprim
20th Mar 20187:00 amRNSMotif Bio Update on NDA Submission for Iclaprim
19th Mar 20187:00 amRNSMotif Bio to present at upcoming conferences
13th Mar 20183:55 pmRNSChange of Registered Office
7th Mar 201812:29 pmRNSExercise of Warrants
1st Mar 20187:00 amRNSGrant of share options to senior management
21st Feb 20187:00 amRNSMotif Bio to Present Iclaprim Data at ECCMID 2018
19th Feb 201812:53 pmRNSExercise of Warrants
2nd Feb 20183:00 pmRNSAppointment of Interim Chief Financial Officer
29th Jan 201812:07 pmRNSSecond Price Monitoring Extn
29th Jan 201812:02 pmRNSPrice Monitoring Extension
19th Jan 20187:00 amRNSFiling of U.S. Shelf Registration
16th Jan 20187:00 amRNSMotif Bio Receives Award from CF Foundation
12th Jan 20183:12 pmRNSHolding(s) in Company
11th Jan 20183:07 pmRNSHolding(s) in Company
8th Jan 20183:23 pmRNSExercise of Warrants
5th Jan 20187:00 amRNSMotif Bio to participate in panel discussion
22nd Dec 20177:01 amRNSNotes statement from Amphion Innovations
21st Dec 20171:00 pmRNSREVIVE-1 additional results published
14th Dec 20177:00 amRNSFiling of SEC Form F-3
28th Nov 20176:24 pmRNSHolding(s) in Company
17th Nov 20177:00 amRNSHolding(s) in Company
17th Nov 20177:00 amRNSExercise of Warrants
15th Nov 20177:00 amRNSSecures up to US$20 million debt financing
9th Nov 20172:40 pmRNSExercise of Warrants
6th Nov 201712:29 pmRNSHolding(s) in Company
18th Oct 20177:00 amRNSHolding(s) in Company
6th Oct 20171:20 pmRNSHolding(s) in Company
6th Oct 20177:00 amRNSNew Pre-Clinical Data for Iclaprim at IDWeek 2017
5th Oct 20179:57 amRNSHolding(s) in Company
4th Oct 20177:00 amRNSPositive Topline Results in Phase Three Study
29th Sep 20177:00 amRNSHalf-year Report
25th Sep 20177:01 amRNSHolding(s) in Company
15th Sep 20172:07 pmRNSiclaprim granted Orphan Drug Designation by US FDA
8th Sep 20171:00 pmRNSHost Investor and Analyst Event on September 20
31st Aug 20171:00 pmRNSCompany to present at conferences in September
30th Aug 20177:00 amRNSHolding(s) in Company
9th Aug 20177:00 amRNSREVIVE 2 Trial Last Patient Treated
18th Jul 20177:00 amRNSAmendment to Amphion Consultancy Agreement
6th Jul 20177:00 amRNSPRESENTING THREE POSTERS ON ICLAPRIM AT ID WEEK
28th Jun 201712:41 pmRNSExercise of warrants
27th Jun 20177:00 amRNSHolding(s) in Company
22nd Jun 20173:20 pmRNSResult of General Meeting
22nd Jun 20177:00 amRNSPresents at ID Week 2017
15th Jun 20175:42 pmRNSResults of Annual General Meeting
14th Jun 20177:00 amRNSPresentation at BIO International Convention

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.